Moderna shares surge as melanoma vaccine with Merck succeeds in large trial

5

By Julie Steenhuysen CHICAGO, Aug 19 (Reuters) – Moderna's mRNA vaccine combined with Merck's immunotherapy Keytruda succeeded in a late-stage trial for skin cancer, the companies said on Wednesday,

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)